Published in BMC Nephrol on April 04, 2013
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients | NCT01209403
Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability. EMBO Mol Med (2016) 0.85
Short-term, low-dose GH therapy improves insulin sensitivity without modifying cortisol metabolism and ectopic fat accumulation in adults with GH deficiency. J Clin Endocrinol Metab (2014) 0.77
PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget (2015) 0.75
Effects of human insulin and insulin aspart preparations on levels of IGF-I, IGFBPs and IGF bioactivity in patients with type 1 diabetes. BMC Endocr Disord (2014) 0.75
A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int (2007) 4.68
What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr (1987) 4.21
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int (2005) 2.78
Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant (2002) 1.99
Inflammatory signals associated with hemodialysis. Kidney Int (2002) 1.69
Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J (2011) 1.67
Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res (2004) 1.50
Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol (2009) 1.43
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med (1993) 1.36
Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest (1995) 1.31
A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab (2003) 1.30
Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab (2002) 1.26
Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases plasma free IGF-I and muscle protein synthesis. Endocrinology (2003) 1.17
Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest (2002) 1.15
Circulating bacterial-derived DNA fragments and markers of inflammation in chronic hemodialysis patients. Clin J Am Soc Nephrol (2008) 1.11
Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol (2006) 1.11
Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul (1995) 1.08
Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int (2008) 1.04
Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol (2004) 1.00
The effects of infusion of insulinlike growth factor (IGF) I, IGF-II, and insulin on glucose and protein metabolism in fasted lambs. J Clin Invest (1991) 0.99
Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. Am J Physiol (1994) 0.97
Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab (2003) 0.97
The phosphorylation pattern of insulin-like growth factor-binding protein-1 in normal plasma is different from that in amniotic fluid and changes during pregnancy. J Clin Endocrinol Metab (1994) 0.96
Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant (2007) 0.96
IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis. Am J Physiol (1996) 0.90
Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int (1999) 0.87
The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol (Oxf) (1993) 0.87
The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest (1993) 0.87
Coordinated increase in albumin, fibrinogen, and muscle protein synthesis during hemodialysis: role of cytokines. Am J Physiol Endocrinol Metab (2004) 0.86
Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. J Am Soc Nephrol (2005) 0.86
Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab (2003) 0.86
Protein turnover and amino acid transport kinetics in end-stage renal disease. Am J Physiol Endocrinol Metab (2003) 0.86
Changes in circulating biomarkers during a single hemodialysis session. Hemodial Int (2012) 0.84
The effect of oral glucose on serum free insulin-like growth factor-I and -II in health adults. J Clin Endocrinol Metab (1997) 0.83
Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol (2004) 0.83
Quantification of the GH/IGF-axis components: lessons from human studies. Domest Anim Endocrinol (2011) 0.82
Cytokine patterns and survival in haemodialysis patients. Nephrol Dial Transplant (2009) 0.82
Multimodal approach to malnutrition in malnourished maintenance hemodialysis patients. J Ren Nutr (2011) 0.82
Marked reductions in bioactive insulin-like growth factor I (IGF-I) during hemodialysis. Growth Horm IGF Res (2009) 0.81
Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin Endocrinol (Oxf) (2004) 0.81
Suppression of endogenous insulin secretion regulates the rapid rise of insulin-like growth factor binding protein (IGFBP)-1 levels following acute hypoglycaemia. Clin Endocrinol (Oxf) (1993) 0.80
Uremia attenuates growth hormone-stimulated insulin-like growth factor-1 expression, a process worsened by inflammation. Kidney Int (2010) 0.79
Insulin is protein-anabolic in chronic renal failure patients. J Am Soc Nephrol (2003) 0.79
Tissue-specific regulation of IGF-I and IGF-binding proteins in response to TNFalpha. Growth Horm IGF Res (2001) 0.78
Anti-inflammatory effect of an insulin infusion in patients on maintenance haemodialysis: a randomized controlled pilot study. Nephrology (Carlton) (2011) 0.77
Removal of hormones by hemofiltration and hemodialysis with a highly permeable polysulfone membrane. Contrib Nephrol (1985) 0.77
Effect of a single hemodialysis session on inflammatory markers. Hemodial Int (2010) 0.76
Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients. Nephrol Dial Transplant (2009) 0.76
Haemodialysis with the biocompatible high permeability AN-69 membrane does not alter plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3. Nephrol Dial Transplant (2001) 0.76
Clinical evaluation of plasma insulin and C-peptide levels with 3 different high-flux dialyzers in diabetic patients on hemodialysis. Int J Artif Organs (2008) 0.76
Insulin-like growth factor-binding protein-1 response to insulin during suppression of endogenous insulin secretion. Metabolism (1993) 0.76
Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humans. Diabetes (1990) 0.76
Prevention and early detection of vascular complications of diabetes. BMJ (2006) 4.14
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology (2003) 3.59
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int (2008) 3.27
Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation (2005) 2.81
Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol (2005) 2.75
Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol (2008) 2.57
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int (2004) 2.42
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
Whey and casein labeled with L-[1-13C]leucine and muscle protein synthesis: effect of resistance exercise and protein ingestion. Am J Physiol Endocrinol Metab (2010) 1.82
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev (2004) 1.74
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes (2002) 1.69
Low IGF-I and elevated testosterone during puberty in subjects with type 1 diabetes developing microalbuminuria in comparison to normoalbuminuric control subjects: the Oxford Regional Prospective Study. Diabetes Care (2003) 1.68
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2011) 1.67
Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. Eur Heart J (2007) 1.63
Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens (2009) 1.61
Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab (2006) 1.61
Adiponectin and lipoprotein particle size. Diabetes Care (2009) 1.60
Tight glycemic control protects the myocardium and reduces inflammation in neonatal heart surgery. Ann Thorac Surg (2010) 1.59
Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes (2004) 1.59
Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr Nephrol (2010) 1.55
The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care (2006) 1.52
Systemic Inflammatory Response and Potential Prognostic Implications After Out-of-Hospital Cardiac Arrest: A Substudy of the Target Temperature Management Trial. Crit Care Med (2015) 1.51
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes. Heart (2012) 1.47
Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr Nephrol (2013) 1.46
Human growth hormone responses to repeated bouts of sprint exercise with different recovery periods between bouts. J Appl Physiol (1985) (2005) 1.45
Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology (2012) 1.44
Aortic pulse wave velocity results depend on which carotid artery is used for the measurements. J Hypertens (2013) 1.43
Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites. Am J Gastroenterol (2003) 1.41
Diagnosis of the syndrome of inappropriate secretion of antidiuretic hormone. South Med J (2009) 1.40
Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. Biomaterials (2006) 1.38
Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. J Physiol (2009) 1.36
Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care (2005) 1.35
Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol (2006) 1.34
Assessment of early diabetic renal changes with hyperpolarized [1-(13) C]pyruvate. Diabetes Metab Res Rev (2013) 1.34
The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system. Clin Epidemiol (2012) 1.32
Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab (2007) 1.31
Cardiovascular disease and insulin-like growth factor I. Circulation (2002) 1.30
A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab (2003) 1.30
Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol (2006) 1.29
Evidence of a causal relationship between adiponectin levels and insulin sensitivity: a Mendelian randomization study. Diabetes (2012) 1.27
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
One-year mortality among Danish intensive care patients with acute kidney injury: a cohort study. Crit Care (2012) 1.22
Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol (2009) 1.18
Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol (2012) 1.17
Fasting unmasks a strong inverse association between ghrelin and cortisol in serum: studies in obese and normal-weight subjects. J Clin Endocrinol Metab (2004) 1.17
Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann Rheum Dis (2012) 1.17
Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology (2007) 1.16
Ghrelin and its relationship to growth hormones during normal pregnancy. Clin Endocrinol (Oxf) (2005) 1.15
Effect of estrogen on tendon collagen synthesis, tendon structural characteristics, and biomechanical properties in postmenopausal women. J Appl Physiol (1985) (2008) 1.13
Gender differences of oligomers and total adiponectin during puberty: a cross-sectional study of 859 Danish school children. J Clin Endocrinol Metab (2007) 1.12
Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab (2008) 1.12
Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J (2008) 1.11
How to start the late referred ESRD patient urgently on chronic APD. Nephrol Dial Transplant (2006) 1.10
Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes (2005) 1.10
Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin. Crit Care (2009) 1.10
Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab (2014) 1.09
Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med (2006) 1.09
Basal and insulin mediated VLDL-triglyceride kinetics in type 2 diabetic men. Diabetes (2010) 1.07
Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. Am J Physiol Endocrinol Metab (2006) 1.07
Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2004) 1.06
Complement activation and diabetic vascular complications. Clin Chim Acta (2005) 1.06
Structural basis for inhibition of complement C5 by the SSL7 protein from Staphylococcus aureus. Proc Natl Acad Sci U S A (2010) 1.06
Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology (2012) 1.05
Five-year risk of end-stage renal disease among intensive care patients surviving dialysis-requiring acute kidney injury: a nationwide cohort study. Crit Care (2013) 1.04
Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care (2008) 1.04
Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J (2010) 1.04
Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol (2006) 1.03
Expression of insulin-like growth factor I, insulin-like growth factor binding proteins, and collagen mRNA in mechanically loaded plantaris tendon. J Appl Physiol (1985) (2006) 1.01
Incidence of GH deficiency - a nationwide study. Eur J Endocrinol (2006) 1.01